Suraksha Diagnostic Limited is the largest integrated diagnostic chain in Eastern India, providing a comprehensive one-stop solution for pathology, radiology, and medical consultation services. The company maintains a dominant market position across **West Bengal, Bihar, Assam, and Meghalaya**, primarily serving the **B2C** segment, which accounts for **94%** of its total revenue. --- ### **Strategic Regional Dominance & Hub-and-Spoke Infrastructure** Suraksha utilizes a sophisticated **Hub & Spoke** operating model to achieve economies of scale and penetrate underserved markets in Eastern and North-Eastern India. This model allows the company to centralize complex testing while maintaining a wide physical footprint for patient convenience. **Operational Asset Inventory (as of Sept/Dec 2025):** | Asset Category | Count | Details / Specifications | | :--- | :--- | :--- | | **Diagnostic Centres** | **66** | Includes **14 Large**, **11 Medium**, and **24 Small** centres | | **Collection Centres** | **173** | Facilitates sample reach in remote clusters | | **Laboratories** | **8** | Includes **1 Central Reference Lab** (CAP accredited) | | **Polyclinic Chambers** | **132** | Hosting **360** doctors for outpatient consultations | | **Imaging Equipment** | **45** | **16 MRI** machines and **29 CT** machines | | **Test Menu** | **2,300+** | Spanning pathology, radiology, and genomics | **Clinical Accreditations:** The company’s commitment to quality is validated by **CAP** (College of American Pathologists) accreditation for its Central Lab, **4 NABL** accredited laboratories, and **3 NABH** accredited advanced diagnostic centres. --- ### **Integrated Service Ecosystem & Specialized Verticals** Suraksha differentiates itself from pure-play pathology labs by integrating clinical services with advanced technology and doctor consultations, creating a high-barrier-to-entry ecosystem. * **The One-Stop Model:** Combines pathology (blood tests, genomics) and radiology (MRI, CT Scan, USG, X-Ray, Cardiology, Neurology) with on-site polyclinics. This integration drives higher "tests per patient" and enhances patient loyalty. * **Suraksha Genomics (Suraksha Sutra):** Launched in **July 2025** with an initial investment of **₹22 Cr** (and **₹46 Cr** additional planned). It is the only commercial genomic lab in Eastern India, utilizing **AI-driven Next-Generation Sequencing (NGS)** for prenatal, oncology, and rare disease segments. * **Fetomat Wellness Acquisition:** Suraksha acquired a **63% stake** in **Fetomat Wellness Private Limited** in April 2025 for **₹5.19 Cr**. Following the hive-off of its IVF business in **December 2024**, Fetomat focuses on specialized fetal and maternal diagnostic services. * **Public-Private Partnerships (PPP):** The company engages in institutional partnerships, including an SPV for a **1.5 Tesla MRI** at Kolkata Medical College. --- ### **Advanced Clinical Infrastructure & Digital Ecosystem** Operations are underpinned by a robust, integrated digital framework designed to minimize human error and optimize turnaround time (**TAT**). * **LIMS & Automation:** A Laboratory Information Management System featuring **bi-directional analyser integration** and barcoded labeling. * **RIS & PACS:** Streamlines radiology workflows with **3D imaging tools** and remote analysis capabilities, allowing specialists to review scans from any location. * **The "Iron Vault" Protocol:** A proprietary data security protocol ensuring that sensitive genetic data from the Genomics vertical remains encrypted and anonymous. * **AI Integration:** Utilization of **AI and Machine Learning** for diagnostic accuracy and "smart lab" operations. --- ### **Financial Performance & Efficiency Metrics** The company demonstrates high efficiency and premium positioning, with a clear correlation between center maturity and profitability. **Key Performance Indicators (KPIs):** | Metric | FY24 | FY25 | 9M FY26 | | :--- | :---: | :---: | :---: | | **Revenue per Patient** | ₹1,925 | **₹2,118** | **₹2,140** | | **EBITDA per Patient** | ₹650 | **₹715** | **₹686** | | **EBITDA Margin** | ~34% | **34%** | **~32%** | | **Tests per Patient** | - | **5.42** | - | | **Revenue per Lab** | - | - | **₹28.6 Cr** | **Profitability Trends:** * **Network Maturity:** Mature centers (**>2 years old**) maintain a robust **37% EBITDA margin**, while newer centers (**12–15 months**) operate at approximately **21%**. * **Growth Impact:** Aggressive expansion (adding **15–20 centers annually**) has caused short-term margin compression. In **Q1 FY26**, pre-operating losses for new centers totaled **₹3 Cr to ₹4 Cr**. * **FY25 Full Year Results:** EBITDA grew by **16%** to **₹85.09 Cr**, and PAT increased by **34%** to **₹30.98 Cr**. --- ### **Growth Strategy & Market Opportunity** Suraksha is positioning itself to capitalize on the **10.5%–12.5% CAGR** projected for the East India diagnostic market through **FY28**. * **Expansion Targets:** In **9M FY26**, the company added **12 operational centers**, with **6 more under development**. The goal is to replicate the West Bengal cluster success in **Bihar, Guwahati, and Meghalaya**. * **Pricing Power:** The Eastern region offers **premium pricing** opportunities due to a lower density of accredited facilities relative to the population. * **Revenue Guidance:** Management has targeted **15% revenue growth** for **FY26** with sustainable long-term **EBITDA margins between 33% and 34%**. * **Talent Retention:** The **Suraksha Employee Stock Option Scheme 2024** (up to **5,00,000 options**) has been implemented to retain key personnel during the scaling phase. --- ### **Risk Factors & Operational Headwinds** Investors should monitor several internal and external factors that may influence short-term performance. * **Leadership Transition:** The **Group CFO, Mr. K S Ravindra**, resigned effective **May 31, 2026**, necessitating a transition in financial leadership. * **Regulatory Shifts:** The company is adapting to the **New Labour Codes (2020)**. While the current impact is deemed **non-material**, final notification of State and Central rules could require financial adjustments. * **External Disruptions:** Recent performance was impacted by the **IPO process**, **regional doctors' strikes**, and **geopolitical instability in Bangladesh**, which affects medical tourism and cross-border patient flow. * **Seasonality:** Diagnostic demand is typically higher in the **third quarter** (post-September), making H1 results less indicative of full-year performance.